Search

Displaying results 2841 - 2850 of 10000 in total
  1. Drug

    Elafibranor

    go.drugbank.com/drugs/DB05187
    ApprovedInvestigational

    Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]

  2. Drug

    Iodide I-123

    go.drugbank.com/drugs/DB09420
    ApprovedInvestigational

    Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. … Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared

    Salts: Sodium iodide I-123Synonyms: Iodide ion i-123, I 123
  3. Drug

    Curcumin

    go.drugbank.com/drugs/DB11672
    ApprovedInvestigational

    Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in [Curcuma xanthorrhiza oil]. … It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities [A33166].

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR).

  5. Drug

    DL-dimyristoylphosphatidylglycerol

    go.drugbank.com/drugs/DB11284
    Approved

    DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

  6. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    in 2-hydroxyglutarate (2-HG), a metabolite that participates in tumerogenesis. … Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.

  7. Drug

    Lerodalcibep

    go.drugbank.com/drugs/DB19071
    ApprovedInvestigational

    [L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia … Lerodalcibep is a recombinant fusion protein that binds to and inhibits proprotein convertase subtilisin kexin type 9 (PCSK9).

  8. Drug

    Perflenapent

    go.drugbank.com/drugs/DB11625
    ApprovedInvestigationalWithdrawn

    Dodecafluoropentane is also known as perfluoropentane or perflenapent.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Parachlorophenol

    go.drugbank.com/drugs/DB13154
    ApprovedWithdrawn

    P-chlorophenol is a white crystals with a strong phenol odor. Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.

  10. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    Dexlansoprazole is the R-enantiomer of [DB00448], which is composed of a racemic mixture of the R- and S-enantiomers. … [A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.[L48827]